EVFM
Evofem Biosciences, Inc.·Healthcare
0.01
6.818%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.0052W H: $0.02
EVFM NEWS
businesswire.com
May 18
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as.
businesswire.com
Apr 27
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals, LLC, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize SOLOSEC® (secnidazole) 2g oral granules in sub-Saharan Africa (the Territory). SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial vag.
defenseworld.net
Mar 26
Head-To-Head Survey: Evofem Biosciences (NASDAQ:EVFM) and Ayala Pharmaceuticals (NASDAQ:ADXS)
Valuation and Earnings This table compares Ayala Pharmaceuticals and Evofem Biosciences"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ayala Pharmaceuticals $3.24 million 11.05 -$48.07 million ($5.02) -0.12 Evofem Biosciences $11.39 million 0.10 $52.98 million ($0.03) -0.28 Evofem Biosciences has higher revenue and earnings
businesswire.com
Mar 11
Evofem Reports Fifth Consecutive Year of Net Sales Growth
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health pioneer Evofem reported its fifth consecutive year of top line growth, with 2025 net product sales of more than $20 million.
